赛升药业：拟使用不超过12亿元的自有闲置资金进行投资理财

Group 1 - The core business of Sai Sheng Pharmaceutical is primarily in the pharmaceutical manufacturing sector, accounting for 99.63% of its total revenue for the year 2024 [1] - The company announced a plan to utilize idle funds effectively by investing up to 1.2 billion yuan in financial products, with the aim of increasing financial returns without affecting normal operations [3] - The investment plan is set to be valid for one year from the date of approval at the shareholders' meeting scheduled for August 20, 2025 [3]